Search

Standing together in support of improved access to obesity care

Learn more about how we’re supporting The Obesity Society and their recent consensus statement on obesity to help raise awareness and improve access to care for people living with this chronic medical condition.

FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation

Chronic Kidney Disease

Meet our scientist

Colleagues explain why they chose Boehringer Ingelheim

Meet the Animal Health Partnering Team

Our BD&L team talks about the team culture, why partnering is important and what they’re looking for.

Partnering Days

Corporate Profile

Purchasing

Suppliers are an integral part of our success. We are passionate about solutions and new opportunities to review, improve and optimize our supplier base.

Rising Star Leads with Determination | Boehringer Ingelheim US

Click to find out more on our partnership with the HBA, where we honor a BI colleague as a “Rising Star” to support the advancement of women in health care.

Cooking Up Change: Boehringer Cares Foundation and World Central Kitchen’s Recipe for Fighting Hunger

Our Boehringer Cares team has partnered with World Central Kitchen who aim to address the critical issue of global food insecurity.

New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US

Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.

Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

Schizophrenia: Trial Results Show Advance in Cognition | BI US

Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.

Pushing for Progress

Protecting Humans & Animals | COVID-19 | Boehringer Ingelheim US

Read more on Boehringer Ingelheim's commitment to protecting both humans and animals during the COVID-19 pandemic.

From garbage to garden - Recycling organic waste to contribute to a healthier planet

Jentadueto XR® Medication Guide | PDF | Boehringer Ingelheim US

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

Medical Affairs & Scientific Comms. | Boehringer Ingelheim US

Boehringer Ingelheim is proud to offer a 2-year, rotation-based, Fellowship program within Medical Affairs & Scientific Communications.

Striving to revolutionize mental health research

World Mental Health Day: We are committed to transforming the mental health landscape through precision psychiatry

Accessibility Statement

Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.

A legacy in the making: Working together to spark meaningful change

Discover Jim’s passion for being an advocate for meaningful causes.

Yankees Legend Bernie Williams Teams Up With Multi-Platinum Recording Artist and Actress Jordin Sparks to Unveil New Song Featuring Lyrics From The Breathless® Ballad Challenge Winner

Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers